Cancer Weekly articles from January 1993

Cancer Weekly archives from January 1993

Experimental gene therapy approved. ('compassionate use' for treating brain tumor) (U.S. National Institutes of Health)
January 4, 1993... U.S. NIH Doctors say they've received unprecedented federal approval for "compassionate use" of an unproven gene therapy on a woman dying of a brain tumor. Dr. Ivor Royston, scientific director at the San Diego Regional Cancer...

Taxol approved as treatment for ovarian cancer in U.S. and Canada. (U.S. Food and Drug Administration)
January 4, 1993... U.S. FDA Taxol, a drug extracted from the bark of the Pacific yew tree, received approval from the U.S. Food and Drug Administration (FDA) as a treatment for ovarian cancer. But the FDA said the drug can only slow - not cure -the...

Taxol patient access and reimbursement assistance programs announced. (Bristol-Myers Squibb Co.)
January 4, 1993... Bristol-Myers Squibb Co. Bristol-Myers Squibb Co., New York, New York, announced two programs to ensure that patients with limited financial resources for whom the newly approved anticancer drug Taxol (paclitaxel) is prescribed can...

Radiation exposures from bomb plant linked to cancer; data kept secret for decades. (Mayak facility in Chelyabinsk) (Russia)
January 4, 1993... Russia Previously suppressed research on radiation exposures published in the December 29, 1992, issue of the PSR Quarterly: A Journal of Medicine and Global Survival, reveals new evidence of increased leukemia rates among a half-million...

Onconase gene fusion study begins. (U.S. National Institutes of Health)
January 4, 1993... U.S. NIH Alfacell Corp., Bloomfield, New Jersey, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health (NIH), Bethesda, Maryland, to develop new pharmaceutical drugs from...

Agency and CellPro begin new gene therapy trials on two forms of cancer. (metastatic breast cancer, multiple myeloma) (U.S. National Institutes of Health)
January 4, 1993... U.S. NIH CellPro Inc., Bothell, Washington, and the U.S. National Institutes of Health (NIH) have initiated two new human gene therapy trials using CellPro's Ceprate Stem Cell Concentration System in patients being treated for either...

FDA approves MAb-based cancer imaging agent. (monoclonal antibody)(OncoScint CR/OV) (Cytogen Corp.)
January 4, 1993... Cytogen Corp. Cytogen Corporation, Princeton, New Jersey, announced that the U.S. Food and Drug Administration has granted marketing approval for OncoScint CR/OV, the company's diagnostic agent for colorectal and ovarian adenocarcinoma....

Company successfully produces humanized MAb to treat B-cell lymphomas. (monoclonal antibodies) (Immunomedics Inc.)
January 4, 1993... Immunomedics Inc. Immunomedics Inc., San Diego, California, announced the progress of its efforts to develop humanized monoclonal antibodies that target cancer cells. As presented by Shawn Leung, Ph.D., Immunomedics' Director,...

Scientists report ability to enhance therapeutic value of monoclonal antibodies. (Ixsys Inc.)
January 4, 1993... Ixsys Inc. Scientists from Ixsys Inc., San Diego, California, reported that they can create monoclonal antibodies that are more therapeutically effective than the antibodies produced by the human immune system. In two papers...

Company begins human clinical trials of potentially non-toxic cancer treatment. (EL530) (Elan Pharmaceutical Research Corp.)
January 4, 1993... Elan Pharmaceutical Research Elan Pharmaceutical Research Corp., Gainesville, Georgia, a wholly owned subsidiary of Elan Corp. plc, Athlone, Ireland, announced initiation of human clinical trials for EL530 to determine the safe and...

CBT-1 approved for Phase I tests. (drug designed to combat multidrug resistant cells) (CBA Research Inc.)
January 4, 1993... CBA Research Inc. A cancer drug developed by a Lexington, Kentucky, company will be tested soon on humans with the approval of the U.S. Food and Drug Administration (FDA). The first patients probably will receive CBT-1 sometime in...

Company files IND on anticancer drug. (Investigational New Drug application for GL331) (Genelabs Technologies Inc.)
January 4, 1993... Genelabs Technologies, Inc. Genelabs Technologies, Inc., Redwood City, California announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the clinical evaluation of its...

Company receives notice of U.S. patent allowance for panel of antibodies to treat lymphoma. (IDEC Pharmaceuticals Corp.)
January 4, 1993... IDEC Pharmaceuticals IDEC Pharmaceuticals Corp., La Jolla, California, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering its Specifid panel of antibodies for the treatment of non-Hodgkin's...

Ribi ImmunoChem Research licenses Melacine melanoma theraccine to Biomira. (Canada)
January 4, 1993... Canada Ribi ImmunoChem Research Inc., Hamilton, Montana, announced it has signed a license and supply agreement with Biomira Inc., Edmonton, Alberta, Canada, covering the development and commercialization of Ribi's Melacine melanoma...

Company forms collaboration to advance development of radiotherapy for cancer. (Vestar Inc.)
January 4, 1993... Vestar Inc. Vestar Inc., San Dimas, California, announced that it will collaborate with Neutron Technology Corp., a private company based in Boise, Idaho, to develop a promising type of radiotherapy called boron neutron capture therapy...

Clinical Cancer Center installs newest radiation therapy equipment. (Varian Clinac 2300 C/D linear accelerator) (University of California, Irvine)
January 4, 1993... University of California, Irvine The University of California, Irvine (UCI), Medical Center has installed powerful new equipment for radiation therapy treatments in its Clinical Cancer Center. The Varian Clinac 2300 C/D linear...

Long Island breast cancer rates explainable. (U.S. Centers for Disease Control and Prevention)
January 4, 1993... U.S. CDC A report by the U.S. Centers for Disease Control and Prevention (CDC) has determined that high rates of breast cancer on Long Island, New York, can be attributed to other factors besides the environment. The report found...

Study: employees suffer five times more leukemia and lymphoma deaths. (Kaiser Aluminum & Chemical Corp.)
January 4, 1993... Kaiser Aluminum & Chemical Employees at the Tacoma, Washington, works of Kaiser Aluminum & Chemical Corp. suffered five times more leukemia and lymphoma deaths than normal, a study released by the company shows. But another...

Tobacco prices to rise 30 percent in 1993. (France)
January 4, 1993... France Stepping up its war on smoking, the French National Assembly approved a 30 percent price increase for all tobacco products, with the proceeds to help fight a ballooning budget deficit. The increase, double that earlier...

Phase I trials of new anticancer agents. (National Cancer Institute research grant announcement) (Research Report)
January 4, 1993... AUTHORS: RFA Available: CA-93-07. National Cancer Institute. "Letter of Intent Receipt Date: January 22, 1993. Application Receipt Date: March 23, 1993. Purpose: The Division of Cancer Treatment (DCT), National Cancer Institute...

National Cancer Institute/Minority Access to Research Careers summer training supplement. (Research Report)
January 4, 1993... Phase I Trials of New Anticancer Agents AUTHORS: PAR Number: PAR-93-33. National Cancer Institute. "Application Receipt Date: February 1, 1993. Purpose: The Comprehensive Minority Biomedical Program (CMBP) of the Division of...

Combined modality treatment with radiation and chemotherapy: bleak house or great expectations? (Research Report)
January 4, 1993... Combined Modality Treatment with Radiation and AUTHORS: Ian F. Tannock. Ontario Cancer Institute, Princess Margaret Hospital and the University of Toronto, Toronto, Canada. According to the author's abstract of a presentation to...

Computer-controlled radiation therapy and 3-D treatment planning. (Research Report)
January 4, 1993... AUTHORS: Benedick A. Praass. University of Michigan Medical Center at Ann Arbor. According to the author's abstract of a presentation to the 34th annual meeting of the American Society for Therapeutic Radiology and Oncology, held...

Bone-marrow transplantation for pediatric malignancy. (Research Report)
January 4, 1993... AUTHORS: Richard G. Evans. University of Kansas Medical Center at Kansas City. According to the author's abstract of a presentation to the 34th annual meeting of the American Society for Therapeutic Radiology and Oncology, held...

Digitization and image segmentation for ultrasound imaging: experience with brachytherapy planning for prostate cancer. (Research Report)
January 4, 1993... AUTHORS: Wilfred Sewchand, Tianhu Lei and Pradip P. Amin. University of Maryland Medical Center at Baltimore. According to the authors' abstract of a presentation to the 34th annual meeting of the American Society for Therapeutic...

Oligodendrogliomas: postoperative radiotherapy increases survival. (Research Report)
January 4, 1993... AUTHORS: Brian R. Griffin, Daniel L. Silbergeld, Mitchel S. Berger, William Wisbeck and David E. Gannett. University of Washington Medical Center, Seattle, Washington; and the Providence Cancer Group, Everett, Washington. According to...

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. (Periodical Report)
January 4, 1993... SOURCE: Journal of the National Cancer Institute, December 16, 1992;84(24):1875-1887. The extent of tumor angiogenesis, as measured by a count of microvessels, appears to be a highly significant independent prognostic factor in...

Concurrent radiation therapy, 5-fluorouracil and cisplatin for stage II, III and IV, node-negative, squamous cell head and neck cancer. (Periodical Report)
January 4, 1993... SOURCE: Cancer, December 1, 1992;70(11):2685-2689. The addition of chemotherapy to conventional therapies appears to have value in the treatment of node-negative squamous cell head and neck cancer patients, although randomized trials are...

Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. (Periodical Report)
January 4, 1993... SOURCE: Journal of the National Cancer Institute, December 16, 1992;84(24):1887-1895. An international multistudy review adds to the evidence that dietary fiber reduces the risk of colorectal cancer. Colorectal cancer has long been...

Activity of cisplatin in adenocarcinoma of the pancreas. (Periodical Report)
January 4, 1993... SOURCE: European Journal of Cancer, 1993;29A(2):203-205. Cisplatin showed modest activity in the treatment of advanced pancreatic cancer patients in a study from the European Organization for Research and Treatment of Cancer (EORTC). ...

Allelic loss from chromosome 11 in parathyroid tumors. (Periodical Report)
January 4, 1993... SOURCE: Cancer Research, December 15, 1992;52:6804-6810. Not all parathyroid tumors express allelic loss on chromosome 11, suggesting the existence of other genes involved in the development and/or progression of this subgroup of...

Physicians use new therapy to rid 5-year-old of brain tumor. (bone marrow transplant combined with chemotherapy & radiation for a brain stem glioma) (University of Florida)
January 11, 1993... University of Florida A 5-year-old Georgia girl's inoperable brain stem tumor disappeared after she was treated with a new therapy pioneered by University of Florida physicians in Gainesville, Florida. The child, of Savannah,...

Gene therapy creates brain tumor vaccine in rats. (Case Western Reserve University)
January 11, 1993... Case Western Reserve University Researchers report that by altering certain genes in rat brain tumor cells they have been able to turn on killer immune cells that seek out and attack brain cancers. In a study to be published in the...

Researchers suggest sunscreen may increase cases of melanoma. (Cedric Garland, Frank Garland, Edward Gorham) (University of California, San Diego)
January 11, 1993... University of California, San Diego Sunscreen, widely recommended by doctors as a protection against skin cancer, may actually increase the number of cases of the deadliest type of skin cancer, according to three University of California,...

What are the chances of getting recurrent breast cancer? (Yale University)
January 11, 1993... Yale University Findings from the first prospective cohort study of second primary breast cancer using direct patient interviews suggest that women with a history of benign breast disease prior to diagnosis of an initial breast cancer...

Pregnancy after age 40 may increase risk of breast cancer. (United Kingdom)
January 11, 1993... United Kingdom According to a report from United Press International, British researchers have found that women who have their last child relatively late in life may increase their chances of developing breast cancer. The two-year...

Annual rectal exam may not reduce prostate cancer deaths. (The University of Chicago Medical Center)
January 11, 1993... The University of Chicago Medical Center Even though it may result in earlier detection of some prostate cancers, annual screening of older men by digital-rectal exam does not appear to reduce the number of deaths from the disease...

Uncircumcised men and smokers at greater risk of penile cancer, study says. (Washington)
January 11, 1993... Washington Researchers have found that uncircumcised men and men who smoke seem to run an increased risk of penile cancer, according to a report from United Press International. A study involving 110 men diagnosed with penile cancer...

Exercise may reduce risk of some cancers. (California)
January 11, 1993... California Exercise seems to lower a person's chances of getting some types of cancer, researchers say. But they don't know how far the benefit extends. The field is too new, data are too sketchy and relationships between exercise...

Research finds smokeless tobacco use beginning at age 5. (Arkansas)
January 11, 1993... Arkansas One in four young consumers of smokeless tobacco started using it between ages 5 and 8, greatly increasing their risk of developing cancer, according to researchers. Another 25 percent of users surveyed in the study began...

Agency finds secondhand smoke kills. (U.S. Environmental Protection Agency)
January 11, 1993... U.S. EPA The release of a U.S. Environmental Protection Agency (EPA) report that says secondhand smoke kills could trigger an avalanche of federal, state and local restrictions on smoking in public places, health advocates say. The...

Manufacturers must prove saline implants safe. (breast implants) (U.S. Food and Drug Administration)
January 11, 1993... U.S. FDA The U.S. Food and Drug Administration (FDA) has announced that it will require the manufacturers of saline-filled breast implants to prove that their devices are safe. The review is part of the FDA's ongoing inquiry into...

Scientific panel report on health effects of low-frequency electric and magnetic fields. (American Chemical Society)
January 11, 1993... American Chemical Society An independent panel of scientists recently found evidence inconclusive in linking low-frequency magnetic and electric fields (ELM-EMF) and human health. An executive summary of their report, along with...

Agency approves OncoScint, Indiclor for colorectal, ovarian cancers. (imaging agents) (U.S. Food and Drug Administration)
January 11, 1993... U.S. FDA The U.S. Food and Drug Administration (FDA) has approved OncoScint CR/OV, a monoclonal antibody (MAb) product, together with Indiclor (indium-111 chloride), a highly purified radio-imaging agent, as a new approach to identifying...

Agency funds new studies on endometriosis and fibroid tumors. (U.S. National Institute of Child Health and Human Development)
January 11, 1993... U.S. NICHD Endometriosis and fibroid tumors are common, yet still poorly understood gynecological problems. Fibroids are the most common pelvic tumors in women and occur in 20-25 percent of women of reproductive age. Endometriosis also...

Company announces final Phase II study results with TLC D-99. (liposomal doxorubicin) (Liposome Company)
January 11, 1993... Liposome Company A high response rate and good safety profile were seen with the Liposome Company's TLC D-99 in final results of a Phase II trial of patients with metastatic breast cancer, researchers reported at the 15th Annual San...

New book summarizes antitumor compound research conducted in former USSR. (The Review of Antitumor Substances Investigated in Organizations of the Former USSR) (Brandon Associates)
January 11, 1993... Brandon Associates Brandon Associates, a publisher of specialized titles in the sciences, announced the publication of The Review of Antitumor Substances Investigated in Organizations of the Former USSR. This extensive review of...

Video series for cancer patients and families available. (Putting Cancer in Perspective) (Stanford University)
January 11, 1993... Stanford University Patients faced with a new cancer diagnosis can now receive authoritative information and encouragement about coping with their disease and taking an active part in their treatment via a four-part videotape and...

Experience of the Institut Gustave Roussy in the treatment of intracranial ependymomas of children. (Research Report)
January 11, 1993... Experience of the Institut Gustave Roussy in the AUTHORS: P. Rousseau, J.L. Habrand, D. Sarrazin, C. Kalifa and M.J. Terrier-Lacombe. Institut Gustave Roussy, Villejuif, France. According to the authors' abstract of a poster...

Prognostic factors in stage I and II diffuse large cell lymphoma patients treated with multiagent chemotherapy alone or combined with radiation therapy. (Research Report)
January 11, 1993... AUTHORS: Timothy D. Shafman, Blair J. Beard, Barbara Silver and Peter Mauch. Harvard Medical School, Boston, Massachusetts. According to the authors' abstract of a poster presentation to the 34th annual meeting of the American Society...

Analysis of prognostic factors in localized gastric lymphoma and the importance of bulk of disease. (Research Report)
January 11, 1993... AUTHORS: R.K. Valicenti, T.H. Wasserman, J.A. Brink and N.A. Kucik. Washington University School of Medicine, St. Louis, Missouri. According to the authors' abstract of a poster presentation to the 34th annual meeting of the American...

Management of primary lymphoma of bone. (Research Report)
January 11, 1993... AUTHORS: Robert K. Fairbanks, James A. Bonner, Thomas M. Habermann, Carry Y. Inwards, John G. Strickler, K. Krishnan Unni and John Su. Mayo Clinic, Rochester, Minnesota. According to the authors' abstract of a poster presentation to...

Radiation therapy of HIV-positive non-Hodgkin's lymphoma (NHL). (Research Report)
January 11, 1993... AUTHORS: Alfred Brandon, Joanne Bujnoski, Jeffrey Fiedler, Arnold Markoe, Evelynn Marienberg, Andre Abitbol, Ahmad M. Boota, Marcio A. Fagundes, Shenghan Lai and James Schwade. University of Miami School of Medicine, Miami, Florida, and the...

Natural killer (NK) cell lytic dysfunction and putative NK cell receptor expression abnormality in members of a family with chromosome 3p-linked von Hippel-Lindau disease. (Periodical Report)
January 11, 1993... SOURCE: Journal of the National Cancer Institute, December 16, 1992;84(24):1897-1903. A National Cancer Institute study suggests that certain people with the von Hippel-Lindau disease (VHL) gene might also have a defect in the gene that...

Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. (Periodical Report)
January 11, 1993... SOURCE: Cancer, December 15, 1992;70(12):2778-2783. The immunoreactivity of p53 may be a biologic marker of prognostic significance in colorectal cancer patients, according to a study from a Japanese research center. The expression...

Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. (Periodical Report)
January 11, 1993... SOURCE: Blood, December 15, 1992;80(12):2977-2982. There was an improved leukemia-free survival in young AML patients treated with high-dose cytarabine-based consolidation therapy, but no such benefit was seen for older patients in a...

Cancer incidence and mortality in workers exposed to fluoride. (Periodical Report)
January 11, 1993... SOURCE: Journal of the National Cancer Institute, December 16, 1992;84(24):1903-1909. A Danish study suggests that workers exposed to high levels of fluoride dust may be at increased risk of urinary bladder cancer. More than 260...

CA 15-3 in patients with locoregional and metastatic breast carcinoma. (Periodical Report)
January 11, 1993... SOURCE: Cancer, December 15, 1992;70(12):2831-2834. Increased CA 15-3 levels strongly indicate the presence of occult metastatic disease in patients with breast cancer, according to a report from an Irish research center. ...

Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762). (Periodical Report)
January 11, 1993... SOURCE: Blood, December 15, 1992;80(12):2983-2990. The impact of the BCR-ABL gene on clinical outcome in adult acute lymphoblastic leukemia patients appears to be greater in the maintenance of complete remissions than in achieving those...

Characterization of Kaposi's sarcoma-derived cell cultures from an epidemic and a classic case. (Periodical Report)
January 11, 1993... SOURCE: International Journal of Oncology, December 1992;1(7):723-730. Host factors - and not tumor characteristics - must account for the clinical differences between epidemic and classic Kaposi's sarcoma (KS), an Italian study...

Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression - implications for AIDS-Kaposi's sarcoma pathogenesis. (Periodical Report)
January 11, 1993... SOURCE: Journal of Immunology, December 1992;149(11):3727-3734. Cytokines produced by activated immune cells -perhaps acting in concert with HIV-1 - induce normal vascular cells to become Kaposi's sarcoma (KS) cells and promote their...

British Columbia drug maker prepares to enter taxol production. (Towers Phytochemicals Ltd.) (Canada)
January 18, 1993... DATELINE: Canada A chemical company in British Columbia, Canada, plans to build a facility to extract the anticancer agent Taxol from the bark of the province's Pacific yew trees. Towers Phytochemicals Ltd. already has stockpiled...

New gene marking study sheds light on cancer relapse. (autologous bone marrow transplant while in remission can cause relapse) (St. Jude Children's Research Hospital)
January 18, 1993... DATELINE: St. Jude Children's Research Hospital A study published in the January 9, 1993, issue of the Lancet answers the long-debated question of whether or not autologous bone-marrow transplants - those done with one's own bone marrow -...

New drug technology could "target" medicine to site of disease. (liposome technology) (U.S. Food and Drug Administration)
January 18, 1993... DATELINE: U.S. FDA At least three companies are working on drugs that would go directly to the site of a life-threatening disease or injury rather than circulate randomly through the body. Under experiment are liposomes, or...

Study identifies women least likely to receive mammography and Pap smear screening. (American Cancer Society)
January 18, 1993... DATELINE: American Cancer Society Income is the most important predictor of mammography use, according to new American Cancer Society research which showed that women below the poverty level are at greatest risk of being underserved, but...

Thymosin alpha 1 evaluated in clinical trial in Mexico. (U.S. Food and Drug Administration)
January 18, 1993... DATELINE: U.S. FDA Alpha 1 Biomedicals Inc., Bethesda, Maryland, and its licensee, SciClone Pharmaceuticals Inc., have received approval from the U.S. Food and Drug Administration (FDA) to export Thymosin alpha 1 to Mexico where it will...

Companies sign new hepatitis virus agreement for screening HXV. (hepatitis X virus) (Genelabs Technologies Inc./Abbott Laboratories)
January 18, 1993... DATELINE: Genelabs Technologies Inc./Abbott Laboratories Genelabs Technologies Inc., Redwood City, California, and Abbott Laboratories, Abbott Park, Illinois, announced the signing of a worldwide non-exclusive licensing agreement allowing...

Safety of silicone testicular implants questioned. (U.S. Food and Drug Administration)
January 18, 1993... DATELINE: U.S. FDA The U.S. Food and Drug Administration (FDA) said it may ask makers of silicone testicular implants to give evidence that they are safe and effective. The implants are solid or filled with silicone gel and are...

Colorado lung specialist lauds EPA report on second-hand cigarette smoke. (Dr. Barry Maker) (U.S. Environmental Protection Agency)
January 18, 1993... DATELINE: U.S. EPA A long-delayed report by the U.S. Environmental Protection Agency (EPA) that targets second-hand cigarette smoke as a killer is timely and should help reduce the acceptability of smoking in society, a Denver, Colorado,...

New protection from cigarettes will be sought for children. (New York)
January 18, 1993... DATELINE: New York State health officials and Governor Mario Cuomo are putting the final touches on legislation which would outlaw smoking in schools and toughen rules regulating smoking and tobacco advertising in public places, the...

Dentists can now prescribe smoking cessation drugs. (nicotine patches and gum) (Ohio)
January 18, 1993... DATELINE: Ohio In reaffirming its opposition to the use of tobacco, the Ohio Dental Association (ODA) has urged dentists throughout Ohio to educate patients on new methods to stop smoking. Products that aid in smoking cessation are...

Company, center announce patent allowance. (continuous-flow cell-selection technology) (CellPro Inc./Fred Hutchinson Cancer Research Center)
January 18, 1993... DATELINE: Cellpro Inc./Fred Hutchinson Cancer Center CellPro Inc., Bothell, Washington, and the Fred Hutchinson Cancer Research Center, Seattle, Washington, announced that the U.S. Patent and Trademark Office has allowed three patent...

Doctors say older women still need mammograms. (women over 40) (Rhode Island)
January 18, 1993... DATELINE: Rhode Island Women over 40 should get mammograms every year or two, despite a recent study that questions the cost-effectiveness of testing for women between 40 and 50, Rhode Island doctors say. "The only reason for not...

Dianon Systems Inc. to support market introduction of new imaging technology. (OncoScint CR/OV) (Connecticut)
January 18, 1993... DATELINE: Connecticut Richard A. Sandberg, chairman of Dianon Systems Inc., Stratford, Connecticut, announced that supporting the market introduction of the first of a new class of diagnostic imaging agents for ovarian and colorectal...

Coalition rejects CDC report. (Long Island Breast Cancer Coalition; Centers for Disease Control and Prevention) (New York)
January 18, 1993... DATELINE: New York A U.S. study on Long Island, New York's high breast cancer rate - which attributed it to known risk factors rather than the environment - is "a devastating blow to women," a support group said. The Long Island...

Two firms join in anticancer research. (Magainin Pharmaceuticals Inc./Sandoz Pharmaceuticals Corp.)
January 18, 1993... DATELINE: Magainin Pharmaceuticals/Sandoz Pharmaceuticals Magainin Pharmaceuticals Inc., Plymouth Meeting, Pennsylvania, and Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey, have signed an agreement to develop anticancer...

Companies sign agreement to share molecular research. (Mallinckrodt Medical Inc./Sandoz Pharma Ltd.)
January 18, 1993... DATELINE: Mallinckrodt Medical Inc./Sandoz Pharma Ltd. Mallinckrodt Medical Inc., St. Louis, Missouri, a division of IMCERA Group Inc., and Sandoz Pharma Ltd. of Basel, Switzerland, have signed an agreement to share technology on...

New research center will help map genetic disorders. (University of Iowa College of Medicine)
January 18, 1993... DATELINE: University of Iowa College of Medicine Creating maps showing the locations of genetic disorders on human chromosomes is the primary goal of a $15 million grant to establish a new genetic research center at the University of Iowa...

Researcher knew of taxol's benefits years ago. (Dr. Monroe Wall) (North Carolina)
January 18, 1993... DATELINE: North Carolina Dr. Monroe Wall was about 30 years ahead of the U.S. Food and Drug Administration (FDA) on the benefits of a cancer treatment called Taxol. In the early 1960s, Wall tested plants selected randomly in the...

Hearing planned on taxol pricing. (U.S. House of Representatives)
January 18, 1993... DATELINE: U.S. House of Representatives Bristol-Myers Squibb Company, New York, New York, has put Taxol on the market in the U.S. and Canada with a promise that no woman will be denied the drug if she is unable to pay for it. But...

Company to merge oncology business with Immunex. (Lederle Laboratories; Immunex Corp.) (American Cyanamid Co.)
January 18, 1993... DATELINE: American Cyanamid American Cyanamid Company plans to create a new company specializing in cancer-treatment products by merging its North American Lederle Laboratories with Immunex Corporation. American Cyanamid announced...

Psychiatric/Oncology Liaison Service established. (Paoli Memorial Hospital) (Pennsylvania)
January 18, 1993... DATELINE: Pennsylvania To provide necessary mental support for certain cancer patients and their families when emotional conflicts arise due to the disease, the Department of Psychiatry at Paoli Memorial Hospital (PMH), Paoli,...

Levamisole decreases major histocompatibility complex (MHC) class I expression in colorectal and breast carcinoma cell lines. (Research Report)
January 18, 1993... AUTHORS: R.F. Holcombe, K.H. Goodrich and X. Alvarez. LSU Medical Center, Shreveport, Louisiana. According to the authors' abstract of a poster presentation to the meeting of the Southern Society for Clinical Investigation, to be held...

Is soluble IL-2 receptor level (SIL2R) a reliable prognostic factor in children with acute lymphoblastic leukemia? (Research Report)
January 18, 1993... AUTHORS: D. Ode, S. Kuvibidila, R.P. Warrier and L.C. Yu. LSU Medical Center and Children's Hospital, New Orleans, Louisiana. According to the authors' abstract of a poster presentation to the meeting of the Southern Society for Clinical...